成都先导: 成都先导药物开发股份有限公司关于持股5%以上股东权益变动触及1%刻度的提示性公告

Core Points - The major shareholder, Lhasa Economic and Technological Development Zone Huabo Medical Equipment Co., Ltd., has reduced its stake in Chengdu Xian Dao Pharmaceutical Development Co., Ltd. from 11.17% to 10.92%, triggering a 1% threshold change [1][2] - The reduction in shareholding occurred between August 29, 2025, and September 3, 2025, with a total of 100,000 shares sold [1] - The company confirmed that this change does not violate any prior commitments or plans and does not trigger mandatory tender offer obligations [1][2] Shareholder Information - The shareholder involved in the equity change is Lhasa Economic and Technological Development Zone Huabo Medical Equipment Co., Ltd., which is classified as a significant shareholder [1] - The company has no controlling shareholder or actual controller, and the shareholder does not have any concerted action parties [1] Regulatory Compliance - The equity change does not require the disclosure of an equity change report as per relevant laws and regulations [2] - The company has adhered to the relevant reduction regulations and has timely disclosed the necessary information to investors [2]